Kornimate/medical-research-clean huggingface dataset:
non-damaging photothermal therapy of non-exudative age related macular degeneration

Conditions: Macular Degeneration; Retinal Drusen

Summary: this is a randomized controlled study of non-damaging photothermal macular grid laser versus sham laser therapy in patients with dry age-related macular degeneration (amd) and large high-risk drusen. the goal of the study is to determine if this treatment will reduce macular drusen volume and also whether this might improve visual acuity or reduce the risk of conversion to advanced age-related macular degeneration defined as development of choroidal neovascularization or geographic atrophy.


Eligibility criteria:
inclusion criteria 1. older than 60 years of age. 2. male or female patients with nonexudative amd with a drusen volume of of at least 0.03mm3 in the central 3mm circle 3. adequate pupil dilatation and clear media to perform colour, red-free imaging and fundus fluorescein angiography, fundus autofluorescence imaging and oct. 4. able to give an informed consent. exclusion criteria: 1. presence of signs of advanced amd, such as cnv, haemorrhages or macular atrophy based on oct and fundus autofluorescence photography (faf). 2. previous macular laser treatment. 3. any previous ocular condition that may be associated with a risk of developing macular oedema. 4. vitreomacular traction determined clinically and /or by oct, which in the opinion of the investigator, contributes to the macular oedema (associated or causing a detachment of the fovea). 5. presence of other macular disease such as epiretinal membrane, macular telangiectasia. 6. important known allergies to sodium fluorescein dye used in angiography. 7. ocular or periocular infections. 8. planned intra-ocular surgery within one year. 9. patient is unavailable for follow-up visits.
"death rattle" - a double blind, randomly controlled, crossover trial

Conditions: Noise; Death

Summary: dying patients are often unable to clear secretions from their large airways, resulting in noisy breathing usually described as "death rattle." while there is no evidence that patients find this condition disturbing, the noises may be disturbing to the patient's visitors and caregivers who may fear that the patient is choking to death. in israel none of the pharmaceutical drugs listed in the literature exist. thus, atropine drops which have been noted in the literature as being used, though according to our knowledge no evidence of clinical trials using sublingual atropine were conducted. the study is designed as a randomly controlled, double blind crossover trial. the patient will serve as control for himself, as crossover between placebo and drug (randomly chosen) will take place. the administrator of the drug will be blinded to the medication, each time randomly beginning with a different drug (placebo or atropine). we will evaluate atropine sulphate 1% ophthalmic drops effect on 33 patients using a noise score scale of 0-3. noise scores will be taken at the start; 30 min after drug/placebo administration and every hour thereafter. after 4-hours crossover will take place and evaluation will follow the same protocol.


Eligibility criteria:
inclusion criteria: * : patients belonging to home palliative care unit of clalit health services - southern district, and the oncology department of soroka university medical center and suffering from "death rattle" will be recruited for the study. exclusion criteria: -

Keywords: death rattle noise level primary care
escitalopram in anxiety associated chronic obstructive pulmonary disease (copd) exacerbations

Conditions: Anxiety; COPD

Summary: anxiety and depression are common in patients with severe chronic obstructive pulmonary disease (copd). frequently exacerbation's of breathlessness are associated with panic/fear and indeed this may be the main cause for the for hospital admission. patients prone to a tendency to experience and communicate somatic distress in response to psychosocial stress and to seek medical help for it are top of the "frequent flyer" league, costing the health care economy dearly. this is a particular problem in hull with the high levels of smoking and urban deprivation combining to place the city at the bottom of the department of health copd league tables. our hypothesis is that an effective treatment for anxiety will reduce the number of episodes of hospital admission by reducing the panic/fear element of mild copd exacerbation's thus allowing the patient time to access the existing community based support services.


Eligibility criteria:
inclusion criteria: * male/females aged between 40-80 years. * previous diagnosis of copd confirmed by the gold criteria. * at least two previous admissions to hospital for acute exacerbation of copd. * physician diagnosed anxiety * at least mild anxiety score on hads and gad-7 * on a stable therapeutic regimen for copd for 8 weeks prior to inclusion * known history of cigarette smoking at least 10 pack yrs * willing and able to comply with study procedures * able to provide written informed consent to participate exclusion criteria: * current or past diagnosis of asthma * long-term oxygen therapy * currently on treatment with anti-depressives * serious inter-current illness (eg lung cancer) * one year survival considered unlikely * patients who have evidence of alcohol or drug abuse * participation in another clinical trial with an investigational drug in four weeks preceding the screening visit * clinically significant or unstable concurrent disease e.g. left ventricular failure, diabetes mellitus * known or suspected hypersensitivity to escitalopram

Keywords: exacerbations
study of m2es in patients with advanced pancreatic cancer after gemcitabine treatment failure

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to evaluate the safety and tolerability and determine the recommended dosing for the treatment in patients with advanced pancreatic cancer after fist-line gemcitabine treatment failure.

to evaluate the safety and tolerability and determine the recommended dosing for the treatment in patients with advanced pancreatic cancer after fist-line gemcitabine treatment failure.we star with the dose m2es 15mg,then escalate to 30mg 45mg 60mg,to find the recommended dose in clinic practise.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed pancreatic adenocarcinoma that was not amenable to potentially curative surgery. 2. all patients must have developed progressive disease (pd) while receiving or within 6 months after discontinuing palliative gemcitabine-based chemotherapy 3. prior radiation therapy was allowed provided that the only sites of measurable disease were not located within the radiation port. 4. 18 years of age or older 5. karnofsky performance status (kps) of 60-100 points 6. measurable disease as defined by response evaluation criteria in solid tumors (recist) criteria 7. adequate hematologic, renal, and hepatic function was required as dewned by the following: wbc ≥3.5×109/l, absolute neutrophil count ≥ 1.5 × 109/l, platelet count ≥100 × 109/l, hemoglobin≥9g/dl, total bilirubin ≤2.5 upper limit of normal \[uln\],ast≤2.5 uln, or≤5 uln if there was evidence of liver metastases;alkaline phosphatase≤ 2.5 uln, or≤ 5 uln if there was evidence of liver metastases creatinine clearance≤50 ml/min, 8. life expectancy of at least 12 weeks exclusion criteria: 1. patients had clinically apparent cns metastases or carcinomatous meningitis 2. another active malignancy, or any history of other malignancy within the past 5 years except for nonmelanoma skin cancer and carcinoma in situ of the cervix 3. more than 3 weeks intervals between the last administration of the prior chemotherapy regimen and study entry 4. more than 4 weeks intervals between the last administration of the targeted therapy regimen and study entry 5. major surgery within the prior 6 weeks; 6. pregnant or lactating women 7. tumor involvement of major blood vessels 8. uncontrolled intercurrent illness 9. a history of myocardial infarction or stroke within the last 6 months, uncontrolled hypertension, unstable angina 10. clinically significant cardiac disease (eg, congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication, or myocardial infarction) 11. urine protein ≥ 500 mg in 24 hours; 12. evidence of bleeding diathesis or coagulopathy 13. patients on therapeutic doses of low-molecular weight heparin 14. patients who received thrombolytic agents within the previous month or who required full-dose anticoagulation.
evaluation of infants with intrauterine growth restriction

Conditions: Intrauterine Growth Restriction

Summary: purpose: clinical assessment (anthropometric) and paraclinical (biochemical and immunological by dosing serum insuline growth factors igf1 and igf2 and their receptors) of neonates with intrauterine growth restriction (iugr) and the integration in a multidimensional statistical model . objectives: 1. igf1 and igf2 evaluation of serum and igf1 receptor, igf2 receptor and igf2 receptor gene expression in cord blood from newborns with intrauterine growth restriction (iugr). (prospective) 2. evaluation and monitoring of anthropometric, clinical (non-cardiac morbidity) and paraclinical. (retrospective \& prospective) 3. evaluation and monitoring of morphological and functional by echocardiography. (prospective) 4. integrating multidimensional clinical and paraclinical parameters in a statistical model for evaluating newborn with intrauterine growth restriction.


Eligibility criteria:
inclusion criteria: * newborns with intrauterine growth restriction (iugr): weight below the 10th percentile for gestational age * parental consent for enrollment exclusion criteria: * iugr neonates in the context chromosomopathies: trisomy 21, trisomy 18. * neonates with congenital heart disease * twins * refusal of parents for participation to the study

Keywords: iugr (intrauterine growth restriction) igf2 (insulin-like growth factor 2) morbidity
establishment of an algorithm for a clinical classfication of hypoosmolar hyponatremia

Conditions: Hyponatremia

Summary: the prospective clinical diagnosis of hyponatremia is often very difficult- but requirement for an appropriate and riskless treatment of hyponatremia. this study try to establish an algorithm handling a prospective clinical categorization of hyponatremia and approving together the start of an appropriate symptomatic therapy.


Eligibility criteria:
inclusion criteria: * hypoosmolar hyponatremia with serum sodium concentration ≤129 mmol/l and serum osmolality ≤ 280 mosm/kg; * age \> 18 years; * letter of agreement. exclusion criteria: * gravidity and lactation; * restricted decision-making-ability

Keywords: hyponatremia diagnosis and treatment of hyponatremia classification of hyponatremia
late-covid/late-covid-kids - observational study in children and adults

Conditions: Covid19

Summary: all consecutive patients admitted to the polish mother memorial research institute (pmmhri) in lodz, poland between 1st october 2020 and 31st december 2021 due to symptoms, which might reflect complications following covid-19, will be included in the observational cohort study. data concerning clinical characteristics, results of laboratory tests, other studies, such as: echocardiography, 24 hours ambulatory ecg recording will be collected. the study is planned also to be extended with the genetic predisposition in children to covid-19 late complications (within independent grant).

a wide range of complications have been linked to covid-19 - the coronavirus disease caused by the severe acute respiratory syndrome coronavirus 2 (sars-cov-2). it is well known that covid-19 affects multiple organs. most of the data however present the early complications during the acute phase of the infection, and there is still a lack of knowledge on the late complications that might appear after recovery. additionally, the long-term complications in patients who were asymptomatic or had mild symptoms during the acute phase of infection, not requiring hospitalization, oxygen therapy or mechanical ventilation has not been fully studied. therefore, our aim was to assess factors related to the severity of post-covid complications among patients without severe symptoms in the acute phase of covid-19. the study will include consecutive covid-19 convalescents (the infection of coronavirus was confirmed with real-time polymerase chain reaction test or positive result of autoantibodies) admitted to the departments of polish mother memorial research institute (pmmhri) in lodz, poland, for complications. both children and adults will be included in the study. the patients will have laboratory testing and other studies due to the character of symptoms.

Eligibility criteria:
inclusion criteria: * consecutive covid-19 convalescents (the infection of coronavirus was confirmed with real-time polymerase chain reaction test or positive result of autoantibodies) admitted to the departments of polish mother memorial research institute (pmmhri) in lodz, poland, for complications exclusion criteria: * no history of covid-19 infection, * lack of complications post covid-19, * severe course of sars-cov-2 infection, * lack pf patient's agreement to be included in the study

Keywords: covid-19 post-covid-19 late-covid-19 complications sars-cov-2
intervention study on the health impact of air filters in chinese adults

Conditions: Inflammation; Coagulation; Blood Pressure; Pulmonary Function

Summary: this study aimed to evaluate whether a short-term indoor air purifier intervention improves cardiopulmonary health based on a randomized double-blind crossover trial

we conducted a randomized double-blind crossover trial among 35 healthy college students in shanghai, china in 2014. these students lived in dormitories that were randomized into two groups and alternated the use of true or sham air purifiers for 48 hours with a 2-week wash-out interval.all participants and research staff were blinded to the group assignment. we requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period. we delivered foods and drinks to each room during the intervention period. all interventions started at 8 a.m. to avoid issues related to diurnal variation. we evaluated health endpoints and drew blood immediately after the completion of each 48-hour intervention. we measured 14 circulating biomarkers of inflammation, coagulation and vasoconstriction, lung function, blood pressure (bp), and fractional exhaled nitric oxide (feno).

Eligibility criteria:
inclusion criteria: * healthy college students aged between 18 and 26 * all the subjects should stay indoor almost the entire time, and stayed within the central urban area of shanghai during the wash-out period. exclusion criteria: * current smokers or ever smokers * chronic respiratory diseases * chronic cardiovascular diseases * acute infections * medication use in recent one month

Keywords: air pollution air purification intervention randomized controlled trial cardiovascular health pulmonary health
abductor reattachment methods in proximal femur replacements: what is the best method?

Conditions: Sarcoma; Bone Metastases; Proximal Femur Replacement

Summary: the purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique. the investigators hypothesize that those patients who receive reattachment of the abductors directly into the prosthesis will have better functional outcomes overall. furthermore, the investigators plan to develop a simple, cost effective, and reproducible method to assess abductor function at clinical post-operative visits through plain radiographs.

patients treated for proximal femur replacements at duke university medical center by orthopaedic oncology trained surgeons. the duke deduce database will be used to identify retrospective patients using the above mentioned cpt codes. individual chart review of the electronic medical record will then be used to identify those receiving a proximal femur replacement. maximum number of charts to be reviewed in the study will be 300. of these 300 charts, the investigators plan to consent 25 subjects who have return appointments scheduled. the investigators also plan to consent 25 preoperative patients, for a total of 50 subjects.

Eligibility criteria:
inclusion criteria: • has undergone or is scheduled for proximal femur replacement by an ortho oncology surgeon exclusion criteria: * non-ambulatory before or after the procedure * subjects who, in the opinion of the investigator, have not or likely will not complete at least some portion of the investigator's recommended follow-up
water immersion in chronic stable heart failure

Conditions: Heart Failure

Summary: this study aims to investigate the effects of water immersion and exercise on heart function and blood flow in patients with chronic stable heart failure.


Eligibility criteria:
inclusion criteria: * age \>18 * established diagnosis of heart failure with ntpro bnp \>100 exclusion criteria: * uncontrolled or severe heart failure, defined by nyha class iv symptoms (breathlessness at rest) * severe fluid overload characterised as more than minimal pitting oedema of the ankles only * presence of haemodynamically significant valvular heart disease in the opinion of the investigator * haemoglobin \<125 g/l * weight \>120 kilograms * requiring long term oxygen supplementation in the community * hospitalisation for any cause within the last 6 weeks, that in the opinion of the investigator would affect the patients wellbeing in this study * unstable or severe stable angina that requires three or more antianginals * patients known to have disease causing immunocompromise such as hiv infection or undergoing chemotherapy * patients with active infection * dialysis patients * uncontrolled seizures; patients in whom the pool environment may trigger seizures, new diagnosis of epilepsy * insulin treated diabetic patients with hypoglycaemic episodes in the last 3 months. * pregnant women * central venous lines which are not tunnelled and are exposed superficially. * open access ports to lungs including tracheotomy sites * ventilation tubes for ears * nasogastric or gastrostomy tube in situ * presence of colostomy, ileostomy or urostomy. * presence of open, macerated, infected or non-intact skin or oedema with leakage of serous fluid. * skin condition such as severe eczema or psoriasis * any surgery or invasive devices fitted within the last 4 weeks * any form of mobility impairment requiring mobility aids (e.g. stick or wheelchair) or rendering patient unable to perform gentle exercises, including recent injury or trauma * history of chlorine sensitivity * urinary or faecal incontinence * hydrophobia * unable to give consent
omega-3 pufa for treatment of patients with idiopathic oligoasthenoteratospermia

Conditions: Male Infertility Due to Hypospermatogenesis

Summary: investigators have previously found that sperm quality was not related to obesity indicators, such as body mass index (bmi), waist circumference, waist-hip ratio, girth ratio and serum lipid, but seminal plasma lipids could notably affect the sperm concentration, sperm progressive ratio(pr), sperm dna fragmentation index (dfi). these results indicates that abnormal lipid metabolism in the male reproductive system may affect male fertility. it seems that the sperm fatty acid spectrum is associated with n-3 polyunsaturated fatty acids (pufa) in dietary. docosahexaenoic acid (dha) and eicosapentaenoic acid (epa) are the most common n-3 pufa. only plasma dha/epa may reflect the quantity of dha/epa in adults. most research indicate that n-3 pufa is the main polyunsaturated fatty acid in human sperm. it is well known that diets have great influence on the gut microbiota composition. many researches have delineated the cause and effect relationship between disturbed gut microbes and diseases, such as irritable bowel syndrome, obesity, diabetes. the disturbed gut microbiota ecosystem may also lead to the intestinal mucosal permeability increasing, which may result in endotoxemia and a series of metabolic syndrome. n-3 polyunsaturated fatty acids may play an important role in regulating metabolism and physiological functions in the body. a clinical research found that both total n-3 pufa and dha serum levels were significantly correlated with microbiome alpha diversity. therefore, investigators may try to figure out the influence of n-3 pufa supplement on gut microbiota composition and whether the gut microbiota have influence on sperm parameters. so investigators apply for your permission to collected the fecal samples from the participants, which will be a meaningful work.

in the previous work, investigators found high fat diet induced gut microbiota dysbiosis can lead to low sperm motility and sperm count, and also recognised some microbes which may lead to the low sperm motility and sperm count. it is obvious that gut microbiota can influence the sperm quality. and the supplement of n-3 pufa is significantly correlated with microbiome alpha diversity. so investigators want to collected the fecal samples from the participants, to ascertain whether the supplementation of n-3 pufa can promote sperm parameters by improve gut microbiota ecosystem. the potential microbes planing to cultivate: prevotella spp, bacteroides spp.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of oligoasthenoteratospermia. exclusion criteria: * leukocytospermia, prostatitis, genital trauma, testicular torsion, urinary tract infections, cryptorchidism, varicocele, diabetes, inguinal and genital surgery. * y chromosome microdeletion and chromosomal karyotype abnormality. * extreme oligospermia. * hepatobiliary diseases, kidney failure.

Keywords: male infertility oligoasthenoteratospermia